MARKET

VIVE

VIVE

Viveve Med Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7200
-0.0001
-0.01%
Opening 09:30 05/26 EDT
OPEN
0.7200
PREV CLOSE
0.7201
HIGH
0.7200
LOW
0.7200
VOLUME
3.14K
TURNOVER
539
52 WEEK HIGH
3.220
52 WEEK LOW
0.7200
MARKET CAP
7.66M
P/E (TTM)
-0.2831
1D
5D
1M
3M
1Y
5Y
Viveve to Participate in H.C. Wainwright Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.
ACCESSWIRE · 05/17 20:28
Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report
Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technolog...
ACCESSWIRE · 05/17 12:28
Recap: Viveve Medical Q1 Earnings
Viveve Medical (NASDAQ:VIVE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Viveve Medical reported in-line EPS of $-0.67 versus an estimate of $-0.67.
Benzinga · 05/12 21:12
Viveve Medical GAAP EPS of -$0.67 beats by $0.01, revenue of $1.64M beats by $0.03M
Viveve Medical press release (NASDAQ:VIVE): Q1 GAAP EPS of -$0.67 beats by $0.01. Revenue of $1.64M (+13.1% Y/Y) beats by $0.03M. Increased the installed base of Viveve Systems to 895 systems
Seekingalpha · 05/12 21:00
Viveve Medical Q1 EPS $(0.67), Inline, Sales $1.60M Miss $1.73M Estimate
Viveve Medical (NASDAQ:VIVE) reported quarterly losses of $(0.67) per share which met the analyst consensus estimate. This is a 16.25 percent increase over losses of $(0.80) per share from the same period last year. The
Benzinga · 05/12 20:28
Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update
6 million in Q1 including sale of 2,750 consumable treatment tipsPURSUIT trial top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / May 12, 2022/ Viveve Medical, Inc. (NASDAQ:VIV...
ACCESSWIRE · 05/12 20:01
-- Earnings Flash (VIVE) VIVEVE MEDICAL Reports Q1 Revenue $1.6M, vs. Street Est of $1.61M
MT Newswires · 05/12 16:24
Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022
ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update a...
ACCESSWIRE · 04/28 12:28
More
No Data
Learn about the latest financial forecast of VIVE. Analyze the recent business situations of Viveve Med Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VIVE stock price target is 5.75 with a high estimate of 6.25 and a low estimate of 5.25.
High6.25
Average5.75
Low5.25
Current 0.7200
EPS
Actual
Estimate
-0.58-0.43-0.29-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 17.96M
% Owned: 168.83%
Shares Outstanding: 10.64M
TypeInstitutionsShares
Increased
3
2.41K
New
4
28.10K
Decreased
5
66.37K
Sold Out
5
95.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.27%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Non-Executive Chairman/Independent Director
Steven Basta
Chief Executive Officer/Director
Scott Durbin
Senior Vice President
Jim Robbins
Director
Deborah Jorn
Independent Director
Arlene Morris
Independent Director
Sharon Presnell
No Data
No Data
About VIVE
Viveve Medical, Inc., incorporated on May 10, 2016, designs, develops, manufactures, and markets a platform medical technology, Cryogen-cooled Monopolar Radiofrequency (CMRF). The Company's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI), which is known as Viveve treatment. The Viveve System uses a method of delivering monopolar RF energy for treating tissue, such as Monopolar Radiofrequency Energy. Its Viveve System also uses a cryogen surface cooling that enables volumetric heating of vaginal tissue. Its treatment helps stabilize the underlying hypermobility of the urethra by regenerating collagen around the urethra's bladder neck. The Company's subsidiary includes Viveve, Inc. and Viveve BV.

Webull offers kinds of Viveve Medical Inc stock information, including NASDAQ:VIVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIVE stock methods without spending real money on the virtual paper trading platform.